D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 71 Citations 15,154 207 World Ranking 15130 National Ranking 537

Overview

What is he best known for?

The fields of study he is best known for:

  • Surgery
  • Internal medicine
  • Cancer

Mario Mercuri focuses on Surgery, Chemotherapy, Osteosarcoma, Sarcoma and Internal medicine. His is involved in several facets of Surgery study, as is seen by his studies on Ifosfamide, Survival rate, Amputation, Retrospective cohort study and Survival analysis. The Chemotherapy study combines topics in areas such as Neoadjuvant therapy, Multivariate analysis, Primary tumor and Single institution.

His Osteosarcoma research incorporates themes from Methotrexate, Cisplatin, Regimen, Disease and Pathologic fracture. His Sarcoma research is multidisciplinary, relying on both Cancer, Metastasis and Radiation therapy. Mario Mercuri combines subjects such as Gastroenterology and Oncology with his study of Internal medicine.

His most cited work include:

  • Primary bone osteosarcoma in the pediatric age: State of the art (421 citations)
  • Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. (414 citations)
  • Platelet-derived growth factors enhance proliferation of human stromal stem cells. (355 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Surgery, Chemotherapy, Osteosarcoma, Sarcoma and Internal medicine. Amputation, Radiation therapy, Survival rate, Implant and Retrospective cohort study are subfields of Surgery in which his conducts study. His Chemotherapy research incorporates elements of Regimen and Adjuvant.

His Osteosarcoma research includes themes of Methotrexate, Cisplatin and Primary tumor. His study in Sarcoma is interdisciplinary in nature, drawing from both Cancer, Vincristine and Induction chemotherapy. The various areas that he examines in his Internal medicine study include Gastroenterology and Oncology.

He most often published in these fields:

  • Surgery (69.82%)
  • Chemotherapy (35.64%)
  • Osteosarcoma (31.64%)

What were the highlights of his more recent work (between 2008-2014)?

  • Surgery (69.82%)
  • Sarcoma (26.18%)
  • Osteosarcoma (31.64%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Surgery, Sarcoma, Osteosarcoma, Chemotherapy and Orthopedic surgery. As part of one scientific family, Mario Mercuri deals mainly with the area of Sarcoma, narrowing it down to issues related to the Doxorubicin, and often Vincristine. His biological study spans a wide range of topics, including Spindle cell sarcoma, Fibrous dysplasia and Chondrosarcoma.

His Chemotherapy study is associated with Internal medicine. Mario Mercuri has researched Internal medicine in several fields, including Gastroenterology and Standard treatment. His work deals with themes such as Randomized controlled trial and Methotrexate, which intersect with Ifosfamide.

Between 2008 and 2014, his most popular works were:

  • Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review (297 citations)
  • A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study (194 citations)
  • Giant cell tumor of the extremity: A review of 349 cases from a single institution. (172 citations)

In his most recent research, the most cited papers focused on:

  • Surgery
  • Cancer
  • Internal medicine

Surgery, Sarcoma, Retrospective cohort study, Orthopedic surgery and Osteosarcoma are his primary areas of study. Surgery is closely attributed to Radiology in his study. His Sarcoma research integrates issues from Ifosfamide, Internal medicine, Chemotherapy and Clinical endpoint.

His work carried out in the field of Chemotherapy brings together such families of science as Immunology and Oncology. Mario Mercuri has included themes like Adjuvant, Giant cell, Radiography and Lesion in his Retrospective cohort study study. His research integrates issues of Cancer, Disease, Rare disease, Bone marrow and Resorption in his study of Orthopedic surgery.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Primary bone osteosarcoma in the pediatric age: State of the art

Alessandra Longhi;Costantino Errani;Massimiliano De Paolis;Mario Mercuri.
Cancer Treatment Reviews (2006)

646 Citations

Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.

Gaetano Bacci;Alessandra Longhi;Michela Versari;Mario Mercuri.
Cancer (2006)

608 Citations

Platelet-derived growth factors enhance proliferation of human stromal stem cells.

Enrico Lucarelli;Amira Beccheroni;Davide Donati;Luca Sangiorgi.
Biomaterials (2003)

544 Citations

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Stefano Ferrari;Sigbjorn Smeland;Mario Mercuri;Franco Bertoni.
Journal of Clinical Oncology (2005)

500 Citations

Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review

Eric R. Henderson;John S. Groundland;Elisa Pala;Jeremy A. Dennis.
Journal of Bone and Joint Surgery, American Volume (2011)

404 Citations

Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

Gaetano Bacci;Piero Picci;Stefano Ferrari;Pietro Ruggieri M.D..
Cancer (1993)

386 Citations

Giant cell tumor of the extremity: A review of 349 cases from a single institution.

Costantino Errani;Pietro Ruggieri;Marco Antonio Nogales Asenzio;Angelo Toscano.
Cancer Treatment Reviews (2010)

318 Citations

Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival

Stefano Ferrari;Antonio Briccoli;Mario Mercuri;Franco Bertoni.
Journal of Clinical Oncology (2003)

308 Citations

Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin

G. Bacci;P. Picci;P. Ruggieri;M. Mercuri.
Cancer (1990)

302 Citations

Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities.

P Picci;T Böhling;G Bacci;S Ferrari.
Journal of Clinical Oncology (1997)

265 Citations

Best Scientists Citing Mario Mercuri

Piero Picci

Piero Picci

University of Bologna

Publications: 133

Richard Gorlick

Richard Gorlick

The University of Texas MD Anderson Cancer Center

Publications: 68

John H. Healey

John H. Healey

Memorial Sloan Kettering Cancer Center

Publications: 63

Francis J. Hornicek

Francis J. Hornicek

University of California, Los Angeles

Publications: 60

Stefano Ferrari

Stefano Ferrari

Veneto Eye Bank Foundation

Publications: 55

Peter F. M. Choong

Peter F. M. Choong

University of Melbourne

Publications: 51

Paul A. Meyers

Paul A. Meyers

Memorial Sloan Kettering Cancer Center

Publications: 49

Jay S. Wunder

Jay S. Wunder

University of Toronto

Publications: 46

Alessandro Gronchi

Alessandro Gronchi

University of Milan

Publications: 42

Pancras C.W. Hogendoorn

Pancras C.W. Hogendoorn

Leiden University Medical Center

Publications: 40

Hans Gelderblom

Hans Gelderblom

Leiden University Medical Center

Publications: 40

Franklin H. Sim

Franklin H. Sim

Mayo Clinic

Publications: 36

Mark Krailo

Mark Krailo

University of Southern California

Publications: 36

Paolo G. Casali

Paolo G. Casali

University of Milan

Publications: 34

Ziya L. Gokaslan

Ziya L. Gokaslan

Brown University

Publications: 32

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.